Registration Dossier

Data platform availability banner - registered substances factsheets

Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.

The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.

Diss Factsheets

Administrative data

Description of key information

Key value for chemical safety assessment

Skin sensitisation

Link to relevant study records
Reference
Endpoint:
skin sensitisation: in vivo (LLNA)
Type of information:
experimental study
Adequacy of study:
key study
Reliability:
1 (reliable without restriction)
Rationale for reliability incl. deficiencies:
other: GLP guideline study
Qualifier:
according to guideline
Guideline:
OECD Guideline 429 (Skin Sensitisation: Local Lymph Node Assay)
GLP compliance:
yes (incl. QA statement)
Type of study:
mouse local lymph node assay (LLNA)
Species:
mouse
Strain:
CBA
Sex:
female
Details on test animals and environmental conditions:
TEST ANIMALS
- Source: Harlan Laboratories B.V.; Host /The Netherlands
- Age at study initiation: 1st pre-test: 10 - 11 weeks (beginning of treatment)
2nd pre-test: 8-9 weeks (beginning of treatment) Main study: 11 - 12 weeks (beginning of treatment)
- Housing: group (Makrolon Type II / III)
- Diet (e.g. ad libitum): 2018C Teklad Global 18% protein rodent diet (certified), ad libitum
- Water (e.g. ad libitum): tap water, ad libitum
- Acclimation period: at least 5 days prior

ENVIRONMENTAL CONDITIONS
- Temperature (°C): 22 +/- 2°C
- Humidity (%): approx. 45-65 %
- Photoperiod (hrs dark / hrs light): 12/12

Vehicle:
dimethylformamide
Concentration:
2, 5 and 10% (As the purity of the test item was approx. 50%, the actual tested concentrations were approx. 1, 2.5 and 5% (w/w))
No. of animals per dose:
5 females
Details on study design:
Methode:
Each test group of mice was treated by (epidermal) topical application to the dorsal surface of each ear with test item concentrations of 2, 5, and 10% in DMF (actual concentration of 1, 2.5 and 5%). The application volume, 25 μL/ear/day, was spread over the entire dorsal surface (∅ ∼ 8 mm) of each ear once daily for three consecutive days. A further group of mice (control animals) was treated with an equivalent volume of the relevant vehicle alone (control animals).
Five days after the first topical application (day 6) 250 μL of phosphate-buffered saline containing 19.8 μCi of 3H-methyl thymidine (equivalent to 79.2 μCi/mL 3HTdR) were injected into each test and control mouse via the tail vein.
Approximately five hours after treatment with 3HTdR all mice were euthanised by using CO2, which was, after harvesting of the lymph nodes, followed by cervical dislocation to ensure death.

Positive control substance(s):
hexyl cinnamic aldehyde (CAS No 101-86-0)
Statistics:
A statistical analysis was conducted on the DPM values, the ear weights, the lymph node weights and the lymph node cell count to assess whether the difference was statistically significant between the test item groups and negative control group. For all statistical calculations custom made statistical program ´R` Decision Tree was used. Statistical significance was set at the five per cent level (p < 0.05).
The Dean-Dixon-Test and the Grubb’s test were used for detection of possible outliers (performed with custom made statistical program ´R` Decision Tree).
However, both biological and statistical significance were considered together.
Positive control results:
The sensitivity and reliability of the experimental technique employed was assessed by use of α-hexyl cinnamaldehyde dissolved in acetone/olive oil (4+1, v/v) (compound listed in OECD 429 Guideline) which is known to have skin sensitisation properties in mice. The periodic positive control experiment was performed using CBA/CaOlaHsd mice in April 2014.
Parameter:
SI
Remarks on result:
other: see Remark
Remarks:
In this study Stimulation Indices (S.I.) of 1.11, 1.46, and 2.64 were determined with the test item at concentrations of 2, 5, and 10% (w/w) in DMF, respectively (actual concentration of approx. 1, 2.5 and 5% (w/w)). A clear dose response was observed.

Lymph Node Weights and Cell Counts

The measured lymph node weights and -cell counts of all animals treated were recorded after sacrifice. A statistically significant increase in lymph node weight was observed in the high dose group in comparison to the vehicle control group. A statistically significant increase in lymph node cell count was observed in the mid and high dose group in comparison to the vehicle control group. Furthermore, the cut-off value of 1.55 for a positive response regarding the lymph node cell count index reported for BALB/c mice was exceeded in the high dose group (index of 1.72). The statistically significant increases were considered not to be biologically relevant, as none of the affected dose groups produced an S.I. above 3.

Ear Weights

The measured ear weight of all animals treated was recorded on test day 6 (after necropsy). A statistically significant or biologically relevant increase in ear weights was not observed in any treated group in comparison to the vehicle control group. Furthermore, for BALB/c mice, a cut-off value of 1.1 for the ear weight index was reported for a positive response regarding ear skin irritation. None of the indices determined for the test item treated groups exceeded this threshold.

Test item concentration*

Group Calculation

Mean DPM per animal (2 lymph nodes)a)

SD

S.I.

Vehicle Control Group (DMF)

957.0

191.3

1.00

2% Trimethylcyclohexylammonium sulfate, aqueous solution 50 wt.%

 

1064.2

279.8

1.11

5% Trimethylcyclohexylammonium sulfate, aqueous solution 50 wt.%

 

1400.8

255.0

1.46

10% Trimethylcyclohexylammonium sulfate, aqueous solution 50 wt.%

 

2528.0

449.8

2.64S

a) Mean DPM/animal was determined by dividing the sum of the measured values from lymph nodes of all animals within a group by the number of animals in that group (5 animals)

S Mean DPM value for the group was according to the ANOVA (Dunnett-test) significantly higher than the corresponding control value.

* As the purity of the test item was approx. 50%, the actual tested concentrations were approx. 1, 2.5 and 5% (w/w).

The EC3 value could not be calculated, since all S.I.´s are below the threshold value of 3.

Executive summary:

The test item Trimethylcyclohexylammonium sulfate, aqueous solution 50 wt.% was not a skin sensitiser under the test conditions of this study.

Endpoint conclusion
Endpoint conclusion:
no adverse effect observed (not sensitising)
Additional information:

In this study the test item Trimethylcyclohexylammonium sulfate, aqueous solution 50 wt.% was assessed for its skin sensitising potential using the Local Lymph Node Assay (LLNA) in mice. Test item solution at different concentrations was prepared in the vehicle DMF.

For this purpose a local lymph node assay was performed using test item concentrations of 2, 5, and 10% (w/w). As the purity of the test item was approx. 50%, the actual tested concentrations were approx. 1, 2.5 and 5% (w/w).

In this study Stimulation Indices (S.I.) of 1.11, 1.46, and 2.64 were determined with the test item at concentrations of 2, 5, and 10% (w/w) in DMF, respectively (actual concentration of approx. 1, 2.5 and 5% (w/w)). A clear dose response was observed.

The test item Trimethylcyclohexylammonium sulfate, aqueous solution 50 wt.% was thus not a skin sensitiser under the test conditions of this study.


Migrated from Short description of key information:
LLNA: not sensitising (BASF, 2015)

Justification for selection of skin sensitisation endpoint:
GLP guideline study

Justification for classification or non-classification

Based on the available studies data on skin sensitization testing, the test item would not have to be classified and labelled according to Directive 67/548/EEC (DSD) and according to Regulation (EC) No 1272/2008 (CLP).